Postoperative Radioactive Iodine Ablation Effective in Reducing Disease Recurrence in Low-Risk Thyroid CancerJune 20, 2018
For patients with low-risk thyroid cancer, ablation when indicated could be achieved with 1.1 GBq radioactive iodine after recombinant human thyroid-stimulating hormone (rhTSH) injections, as this combination reduces whole body irradiation and maintains quality of life.
Thymic carcinomas typically express high levels of PD-L1, leading researchers to predict a positive response to pembrolizumab.
The risk of AML decreased after 2 years, returning to baseline within 6 years of WDTC diagnosis, but the risk of CML remained elevated for up to 10 years.
Researchers enrolled 116 patients who were diagnosed with or were suspected of having thyroid cancer. The authors measured the growths' change in diameter to determine a growth pattern.
Patients with ATC have a very poor prognosis and are left with few systemic therapy options.
Significant clinical benefit was found in some patients treated with cabozantinib in the salvage setting.
The USPSTF stated that there was inadequate direct evidence for the benefits of screening.
Researchers are studying regorafenib, a multi kinase inhibitor, as treatment for metastatic medullary thyroid cancer.
Thyroid cancer survivors diagnosed prior to age 40 have an increased risk of developing diseases associated with aging.
Patients with unresected anaplastic thyroid carcinoma who receive greater than 60 Gy of radiation appear to have a longer median overall survival.
Crohn Disease (CD) may increase one's risk of thyroid cancer, according to an article published in Inflammatory Bowel Diseases.
The USPSTF recommends against population-wide screening for asymptomatic thyroid cancer.
For papillary thyroid cancer (PTC), patient age is associated with death in a linear fashion, with no apparent age cut point demarcating survival difference.
Embracing all the myriad variations of the human genome should, in theory, lead to rewards that all can share.
Find information about available non-chemotherapy treatments for thyroid carcinoma, including total thyroidectomy, radiodine treatment, and ablation.
Researchers are identifying new roles for infectious and commensal microbes in facilitating and inhibiting carcinogenesis.
CDC27 mutations may be associated with less aggressive behavior while SLC25A5 mutations may be associated with more aggressive behavior in papillary thyroid carcinomas.
The first-in-class compound CUDC-907 may be promising for anaplastic thyroid cancer and poorly differentiated thyroid cancer.
Long-term recurrence rates appear to be low following the use of recombinant human thyrotropin for postoperative ablation in low-risk thyroid cancer.
Initiating treatment with the mTor inhibitor everolimus followed by the somatostatin analogue pasireotide may be beneficial in advanced thyroid cancer.
Active surveillance in low-risk thyroid cancer may be better than immediate surgery in some patients.
Despite side effects, patients with differentiated thyroid cancer taking lenvatinib may experience better outcomes with close monitoring.
Liquid biopsy may prevent the need for unnecessary biopsies in patients with medullary thyroid carcinoma.
Treatment with everolimus in the RADIANT-3 trial was associated with a median overall survival of 44 months.
Despite reports to the contrary, the prevalence of differentiated thyroid cancer is not increasing.
The risk of mortality is higher for patients with papillary thyroid cancer who harbor both BRAF V600E and TERT promoter mutations.
Researchers have identified estimates for risk of occult nodal disease of patients with papillary thyroid cancer who have undergone surgery.
Vemurafenib showed activity in patients with progressive BRAFV600E mutation-positive papillary thyroid cancer refractory to radioactive iodine.
More imaging tests after treatment does not always lead to an improvement in thyroid cancer patients' chances of survival.
The use of the radioguided sentinel lymph node biopsy (rSLNB) technique may lead to management change in more than 33% of patients with papillary thyroid cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML
- Later-Line Treatments for Metastatic Urothelial Carcinoma of the Bladder